SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $212,629 | -56.5% | 7,712 | -52.5% | 0.00% | – |
| Q2 2023 | $488,467 | -60.1% | 16,250 | -51.9% | 0.00% | – |
| Q1 2023 | $1,224,672 | +298.1% | 33,802 | +292.0% | 0.00% | – |
| Q4 2022 | $307,618 | -75.3% | 8,624 | -76.6% | 0.00% | – |
| Q3 2022 | $1,246,000 | +18.8% | 36,799 | +1.4% | 0.00% | – |
| Q2 2022 | $1,049,000 | -23.7% | 36,280 | -14.7% | 0.00% | – |
| Q1 2022 | $1,374,000 | -81.4% | 42,509 | -83.3% | 0.00% | -100.0% |
| Q4 2021 | $7,403,000 | -8.8% | 253,901 | -16.6% | 0.00% | 0.0% |
| Q3 2021 | $8,119,000 | -78.7% | 304,413 | -75.5% | 0.00% | -66.7% |
| Q2 2021 | $38,182,000 | +81.1% | 1,240,095 | +53.9% | 0.00% | +50.0% |
| Q1 2021 | $21,089,000 | +49.9% | 805,574 | +44.1% | 0.00% | +100.0% |
| Q4 2020 | $14,070,000 | +405.9% | 559,199 | +319.2% | 0.00% | – |
| Q3 2020 | $2,781,000 | -12.3% | 133,409 | -0.1% | 0.00% | – |
| Q2 2020 | $3,172,000 | +37.0% | 133,533 | +3.7% | 0.00% | – |
| Q1 2020 | $2,316,000 | -79.0% | 128,727 | -72.3% | 0.00% | -100.0% |
| Q4 2019 | $11,018,000 | -21.1% | 464,514 | -8.6% | 0.00% | -50.0% |
| Q3 2019 | $13,960,000 | -36.1% | 508,028 | -23.1% | 0.00% | -33.3% |
| Q2 2019 | $21,851,000 | -15.4% | 660,357 | -10.4% | 0.00% | 0.0% |
| Q1 2019 | $25,826,000 | -62.7% | 737,068 | -64.6% | 0.00% | -66.7% |
| Q4 2018 | $69,174,000 | -42.1% | 2,082,315 | -12.2% | 0.01% | -30.8% |
| Q3 2018 | $119,396,000 | +111.9% | 2,371,321 | +151.9% | 0.01% | +116.7% |
| Q2 2018 | $56,337,000 | +2526.4% | 941,300 | +1909.6% | 0.01% | – |
| Q1 2018 | $2,145,000 | +0.4% | 46,841 | -12.6% | 0.00% | – |
| Q4 2017 | $2,136,000 | -19.0% | 53,600 | -18.7% | 0.00% | – |
| Q3 2017 | $2,636,000 | -41.3% | 65,900 | -36.7% | 0.00% | -100.0% |
| Q2 2017 | $4,487,000 | +37.7% | 104,100 | 0.0% | 0.00% | – |
| Q1 2017 | $3,258,000 | -9.7% | 104,100 | -27.2% | 0.00% | – |
| Q4 2016 | $3,608,000 | -74.1% | 142,900 | -74.6% | 0.00% | -100.0% |
| Q3 2016 | $13,930,000 | -36.2% | 563,300 | -47.5% | 0.00% | -33.3% |
| Q2 2016 | $21,849,000 | +13.6% | 1,072,600 | -15.0% | 0.00% | 0.0% |
| Q1 2016 | $19,241,000 | +226.3% | 1,261,700 | +187.6% | 0.00% | +200.0% |
| Q4 2015 | $5,896,000 | -4.2% | 438,700 | +0.0% | 0.00% | 0.0% |
| Q3 2015 | $6,152,000 | -20.0% | 438,500 | -3.2% | 0.00% | 0.0% |
| Q2 2015 | $7,692,000 | – | 453,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |